Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Adjuvant external beam radiation and brachytherapy for vaginal resection margin positive cervical cancer

  • Kim, Donghyun (Department of Radiation Oncology and Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Ki, Yongkan (Department of Radiation Oncology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine) ;
  • Kim, Wontaek (Department of Radiation Oncology and Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Park, Dahl (Department of Radiation Oncology and Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Lee, Joohye (Department of Radiation Oncology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine) ;
  • Lee, Jayoung (Department of Radiation Oncology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine) ;
  • Jeon, Hosang (Department of Radiation Oncology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine) ;
  • Nam, Jiho (Department of Radiation Oncology and Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine)
  • Received : 2018.02.27
  • Accepted : 2018.05.03
  • Published : 2018.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the treatment outcomes of adjuvant external beam radiation therapy (EBRT) and vaginal brachytherapy (VB) following radical hysterectomy in cervical cancer patients with involved vaginal resection margin (VRM). Materials and Methods: We retrospectively reviewed the medical records of 21 patients treated with postoperative EBRT and VB for positive VRM FIGO stage IB-IIA cervical cancer between 2003 and 2015. Concurrent platinum-based chemotherapy was administered to all patients. Results: The median whole pelvis EBRT dose was 50.4 Gy (range, 45 to 50.4 Gy). In the VB, the median dose per fraction, number of fractions, and total dose delivered were: 4 Gy (range, 3.0 to 4.0 Gy), 4 fractions (range, 3 to 5 fractions), and 16 Gy (range, 12 to 20 Gy), respectively. At a median follow-up of 46 months (range, 9 to 122 months), local recurrence was observed in 2 patients, and distant metastasis was present in 7 patients. All patients with local recurrence subsequently developed distant metastases. The 5-year local control, disease-free survival, and overall survival rates were 89.1%, 65.9%, and 62.9%, respectively. Of the 21 patients, 7 patients (33.3%) reported grade 2 acute toxicity; however, there were no grade 3 or higher acute adverse events. Grade 1-2 late toxicities were observed in 8 patients. Late grade 3 urinary toxicity was reported in 1 patient. Conclusions: Adjuvant EBRT and VB showed excellent local control and low toxicity in cervical cancer patients with positive VRM. Although limited by its retrospective nature, the findings from our study provide evidence supporting the use of additional VB in pathologically involved VRM.

Keywords

References

  1. Sevin BU, Nadji M, Lampe B, et al. Prognostic factors of early stage cervical cancer treated by radical hysterectomy. Cancer 1995;76(10 Suppl):1978-86. https://doi.org/10.1002/1097-0142(19951115)76:10+<1978::AID-CNCR2820761313>3.0.CO;2-K
  2. Scholten AN, van Putten WL, Beerman H, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: longterm outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005;63:834-8. https://doi.org/10.1016/j.ijrobp.2005.03.007
  3. Alektiar KM, Venkatraman E, Chi DS, Barakat RR. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys 2005;62:111-7. https://doi.org/10.1016/j.ijrobp.2004.09.054
  4. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomized trial. Lancet 2010;375:816-23. https://doi.org/10.1016/S0140-6736(09)62163-2
  5. Small W Jr, Beriwal S, Demanes DJ, et al. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy 2012;11:58-67. https://doi.org/10.1016/j.brachy.2011.08.005
  6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) - cervical cancer [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; c2018 [cited 2018 Jun 1]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.
  7. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103-4. https://doi.org/10.1016/j.ijgo.2009.02.012
  8. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 and Common Toxicity Criteria (CTC) [Internet]. Bethesda, MD: National Institutes of Health; c2018 [cited 2018 Jun 1]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
  9. Nag S, Gupta N. A simple method of obtaining equivalent doses for use in HDR brachytherapy. Int J Radiat Oncol Biol Phys 2000;46:507-13. https://doi.org/10.1016/S0360-3016(99)00330-2
  10. Huh SJ, Kim WD, Ha SW, et al. Postoperative radiotherapy in carcinoma of the cervix with microscopically positive resection margin. Int J Clin Oncol 1997;2:147-51. https://doi.org/10.1007/BF02490125
  11. Averette HE, Nguyen HN, Donato DM, et al. Radical hysterectomy for invasive cervical cancer: a 25-year prospective experience with the Miami technique. Cancer 1993;71(4 Suppl):1422-37. https://doi.org/10.1002/cncr.2820710407
  12. Lai CH, Hong JH, Hsueh S, et al. Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases: an analysis of 891 cases. Cancer 1999;85:1537-46. https://doi.org/10.1002/(SICI)1097-0142(19990401)85:7<1537::AID-CNCR15>3.0.CO;2-6
  13. Estape RE, Angioli R, Madrigal M, et al. Close vaginal margins as a prognostic factor after radical hysterectomy. Gynecol Oncol 1998;68:229-32. https://doi.org/10.1006/gyno.1998.4960
  14. Ampil F, Datta R, Datta S. Elective postoperative external radiotherapy after hysterectomy in early-stage carcinoma of the cervix. Is additional vaginal cuff irradiation necessary? Cancer 1987;60:280-8. https://doi.org/10.1002/1097-0142(19870801)60:3<280::AID-CNCR2820600303>3.0.CO;2-1
  15. Atkovar G, Uzel O, Ozsahin M, et al. Postoperative radiotherapy in carcinoma of the cervix: treatment results and prognostic factors. Radiother Oncol 1995;35:198-205. https://doi.org/10.1016/0167-8140(95)01570-7

Cited by

  1. Significance of the number of high-risk factors in patients with cervical cancer treated with radical hysterectomy and concurrent chemoradiotherapy vol.157, pp.2, 2018, https://doi.org/10.1016/j.ygyno.2020.02.031
  2. Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer vol.30, pp.8, 2018, https://doi.org/10.1136/ijgc-2020-001412
  3. Preoperative controlling nutritional status (CONUT) score is a prognostic factor for early-stage cervical cancer patients with high-risk factors vol.162, pp.3, 2018, https://doi.org/10.1016/j.ygyno.2021.06.012